WINT Stock Price, Chart, Stats & News
Windtree Therapeutics, Inc. (WINT) does not currently pay a dividend.
WINT chart
Fundamentals
Gross margin | 12.22% |
Operating margin | -37218.89% |
Pretax margin | -48335.56% |
Net margin | -44447.78% |
Effective tax rate | 8.06% |
ROA | -250.28% |
ROE | -1302.82% |
D/E | -1.11x |
Interest coverage ratio | -68.64x |
WINT valuation
P/E | – |
P/S | 3.75x |
P/B | -0.00x |
P/CF | -0.00x |
P/FCF | -0.02x |
P/OCF | -0.00x |
PEG | -0.00x |
EV multiple | 0.29x |
About
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension. The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure.
Similar securities
Based on sector and market capitalization
